Director

Matt Pauls

Matt Pauls has served as Chair of the Board of Directors and Chief Executive Officer of Savara since 2020. He has more than 25 years of experience in the biopharmaceutical industry developing and commercializing innovative, high-impact therapies for serious diseases, often in areas with no previously approved treatment options.

Prior to joining Savara, Mr. Pauls served as President and Chief Executive Officer and a member of the Board of Directors of Strongbridge Biopharma plc (formerly Nasdaq: SBBP), which was subsequently acquired by Xeris Pharmaceuticals. Earlier in his career, Mr. Pauls served as Chief Commercial Officer of Insmed Incorporated (Nasdaq: INSM), where he led global commercial and technical operations. He also held senior commercial leadership roles at Shire Pharmaceuticals, Bristol Myers Squibb, and Johnson & Johnson.

From 2023 to 2026, Mr. Pauls served on the board of directors of Soleno Therapeutics, including as Lead Independent Director from 2024 until its $2.9 billion acquisition by Neurocrine Biosciences in 2026. He currently serves on the board of directors of Pelthos Therapeutics (NYSE American: PTHS) and Atsena Therapeutics and previously served on the board of directors of Amplo Biotechnology and Zyla Life Sciences, as well as Chair of the Board of Directors of Mast Therapeutics.

Mr. Pauls holds a Bachelor of Science and a Master of Business Administration from Central Michigan University and a Juris Doctor from Michigan State University College of Law.